Future Treatments

Longer lasting Factor 8 and 9 is now available.

For Haemophilia A patients with Inhibitors Roche’s Emicizumab is being included in the UK early access scheme for routine prophylaxis. It is administered as a once weekly subcutaneous injection.
 

Gene Therapy

13 patients with Haemophilia A were injected with a copy of the Factor 8 gene and a year on have normal clotting levels.